CPRX Q3 2024 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$129M+25.3% YoY

Gross Profit

$109M85.0% margin

Operating Income

$51M39.6% margin

Net Income

$44M34.1% margin

EPS (Diluted)

$0.35

QoQ Revenue Growth

+4.9%

Cash Flow

Operating Cash Flow

$73M

Free Cash Flow

$73M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$772M

Total Liabilities

$111M

Stockholders' Equity

$661M

Cash & Equivalents

$442M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$129M	$103M	+25.3%
Gross Profit	$109M	$89M	+23.6%
Operating Income	$51M	-$37M	+236.9%
Net Income	$44M	-$31M	+242.6%

Revenue Segments

Product Revenue Net

$126M98%

License And Other Revenue

$2M2%